查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2011567

癌症免疫療法市場：按治療方法、作用機制、治療階段、給藥途徑、適應症和最終用戶分類－全球市場預測（2026-2032 年）

Cancer Immunotherapy Market by Therapy Type, Mechanism Of Action, Line Of Therapy, Route Of Administration, Indication, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 184 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，癌症免疫療法市場價值將達到 817.4 億美元，到 2026 年將成長至 861.4 億美元，到 2032 年將達到 1,207.5 億美元，複合年成長率為 5.73%。

主要市場統計數據
基準年 2025 817.4億美元
預計年份：2026年 861.4億美元
預測年份 2032 1207.5億美元
複合年成長率 (%) 5.73%

本文對癌症免疫療法的發展歷程進行了基本概述，重點在於臨床進展、營運挑戰以及相關人員。

在持續的臨床進展和監管里程碑的推動下，癌症免疫療法已從一個充滿前景的科學概念發展成為腫瘤治療的核心支柱。過去十年，基於免疫的治療方法重新定義了骨髓惡性腫瘤和日益增多的固態腫瘤的治療模式，並在許多患者亞群中取得了顯著且持久的療效。細胞工程、精準生物標記檢測以及不斷擴充的單株抗體、疫苗和病毒載體庫的進步，推動了這項發展。

重塑免疫腫瘤學的關鍵趨勢包括技術創新、個人化策略以及整個價值鏈運作的現代化。

癌症免疫療法的格局正在經歷一場變革性的轉變，這主要得益於科學突破、監管調整以及相關人員期望的不斷變化。首先，細胞療法，特別是嵌合體抗原受體T細胞（CAR-T細胞）療法的成熟，使其應用範圍從最初在血液系統疾病領域的成功擴展到包括基因修飾構建體和異基因移植等方法，旨在擴大其適用範圍並縮短治療時間。同時，查核點抑制劑的進展也得到了更複雜的免疫調節方法的補充，例如雙特異性分子和新一代抗體，旨在提高特異性並降低毒性。

評估 2025 年關稅政策的變化將如何影響免疫療法所有相關人員的供應鏈、製造策略和市場定位。

美國2025年實施的新關稅政策可能會透過改變成本、供應鏈結構和採購決策，對整個癌症免疫療法生態系統產生累積影響。生物製藥和細胞療法生產所需的關鍵材料——包括專用試劑、一次性耗材、生物製程設備和低溫運輸物流服務——通常來自世界各地。進口關稅的增加和海關摩擦的加劇可能會推高整體成本，迫使企業調整庫存，並加速選擇替代供應商。因此，採購前置作業時間可能會延長，從而對研發進度帶來壓力，因為緊急時應對計畫將成為專案風險管理的關鍵要素。

全面的細分分析揭示了治療方法、作用機制、適應症和臨床實踐如何推動研發和商業化路徑。

一套精細的細分框架揭示了臨床差異和商業性機會如何在不同的治療方法類型、作用機制、治療線、給藥途徑、適應症和最終用戶之間相互交織。基於治療方法類型，該計畫涵蓋癌症疫苗、CAR-T療法、CTLA-4抑制劑、溶瘤病毒療法、PD-1抑制劑和PD-L1抑制劑，每種療法都面臨獨特的研發挑戰和臨床定位考量。疫苗策略著重於抗原選擇和遞送平台，而細胞療法則需要生產創新和以患者為中心的物流。基於作用機制，該領域涵蓋過繼性細胞療法、免疫查核點抑制劑、細胞激素療法、溶瘤病毒療法和疫苗療法。這種機制的多樣性要求制定個體化的生物標記策略、安全監測框架和聯合治療方案，以在控制毒性的同時最大限度地提高療效。

全球免疫療法市場的區域性趨勢，以及有關監管合作、證據產生和生產的策略考量。

區域趨勢影響臨床試驗設計、監管互動、生產投資和市場准入策略，因此需要採取因地制宜的方法，以應對法律規範、報銷機制和醫療基礎設施等問題。在美洲，監管機構和保險公司優先考慮可靠的療效證據和真實世界數據，而大規模研究網路和創投則加速了首次人體試驗和商業化的進程。因此，各機構通常優先在北美進行早期臨床檢驗和與保險公司的合作，以支持更廣泛的市場進入計畫。此外，美洲地區集中的生產和物流能力有利於快速擴大規模，但也需要與醫院和專科診所的管理模式進行密切協調。

競爭動態與夥伴關係策略：揭示執行、製造規模與平台差異化如何驅動長期價值創造

競爭格局的特點是：既有成熟的免疫腫瘤學領導企業，也有許多致力於平台創新、特定適應症或聯合治療的新興生物技術公司。成熟的研發公司利用其龐大的臨床資料集和製造地，確保適應症的廣泛拓展，並與支付方協商基於價值的合約。而小規模的公司則傾向於專注於差異化生物學、新型抗原標靶或能夠提高生產效率和患者可及性的基礎技術。

為協調臨床開發、生產韌性和支付方合作，以加速部署和價值實現，提出切實可行的策略建議。

規劃免疫腫瘤學下一階段的領導者應採取整合科學、營運和商業化的整合策略。首先，應優先考慮模組化開發計劃，以便採用適應性試驗設計和基於生物標記的隊列研究，從而在保持柔軟性的同時，展現顯著的療效，並拓展適應症和聯合治療。儘早與監管機構和支付方溝通至關重要，以便確定具有臨床意義的終點和可接受的證據包，從而支持永續的報銷結果。其次，應透過考慮區域生產基地、自動化和供應商多元化來增強生產的韌性，從而降低地緣政治因素和關稅帶來的干擾，同時確保品質和合規標準。

透過整合專家訪談、監管分析和營運評估等多源調查方法，得出可操作的產業見解。

本研究採用綜合分析方法，結合科學文獻、監管指南、專家訪談和營運調查方法，建構與產業實踐相符的連貫敘事。關鍵的定性資料包括對臨床研究人員、生產經理、保險公司和商業負責人的結構化訪談，揭示了研發和交付過程中實際存在的障礙和促進因素。除訪談外，對同行評審文章、監管核准和公開文件的系統性回顧，確保分析能夠反映最新的科學進展和政策變化。

結論強調，整合科學、實務和商業性策略對於充分發揮免疫腫瘤學的真正潛力至關重要。

癌症免疫療法正處於一個轉折點，科學進步必須與卓越的營運和清晰的策略相輔相成，才能保持其發展勢頭。儘管新的治療方法和聯合治療策略不斷拓展治療選擇，但其最終影響取決於相關人員能否成功應對複雜的生產要求、多樣化的監管預期以及不斷變化的支付方證據需求。那些積極調整研發策略，將基於生物標記的患者篩選、穩健的供應鏈以及符合支付方要求的證據納入其中的機構，將更有能力將臨床潛力轉化為永續的患者獲益。

目錄

第1章 引言

第2章 分析方法

  • 分析設計
  • 分析框架
  • 市場規模預測
  • 數據三角測量
  • 分析結果
  • 分析的前提條件
  • 分析的局限性

第3章執行摘要

  • 首席體驗長的觀點
  • 市場規模和成長趨勢
  • 市佔率分析（2025 年）
  • FPNV定位矩陣（2025）
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 市場進入（GTM）策略

第5章 市場洞察

  • 消費者分析與最終用戶觀點
  • 消費者體驗基準測試
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 成本效益分析（ROI）和成本效益分析（CBA）

第6章：美國關稅的累積影響（2025 年）

第7章：人工智慧（AI）的累積影響（2025 年）

第8章：癌症免疫療法市場：依治療方法分類

  • 癌症疫苗
  • CAR-T療法
  • CTLA-4抑制劑
  • 溶瘤病毒療法
  • PD-1抑制劑
  • PD-L1抑制劑

第9章：按作用機制分類的癌症免疫療法市場

  • 過繼性細胞療法
  • 查核點抑制劑
  • 細胞激素療法
  • 溶瘤病毒療法
  • 疫苗療法

第10章：依治療階段分類的癌症免疫療法市場

  • 一線
  • 從力線開始
  • 第二行
  • 三線

第11章：癌症免疫療法市場：依給藥途徑分類

  • 腫瘤內部
  • 靜脈
  • 皮下

第12章：癌症免疫療法市場：依適應症分類

  • 骨髓惡性腫瘤
    • 白血病
    • 淋巴瘤
    • 多發性骨髓瘤
  • 固體癌
    • 乳癌
    • 結腸癌
    • 肺癌
    • 惡性黑色素瘤

第13章：癌症免疫療法市場：依最終用戶分類

  • 醫院
  • 研究機構
  • 專科診所

第14章 癌症免疫療法市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第15章 癌症免疫療法市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第16章 癌症免疫療法市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第17章：美國癌症免疫療法市場

第18章：中國癌症免疫療法市場

第19章 競爭情勢

  • 市場集中度分析（2025 年）
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析（2025 年）
  • 產品系列分析（2025 年）
  • 基準分析（2025 年）
  • Amgen Inc.
  • AstraZeneca PLC
  • BeiGene, Ltd.
  • bluebird bio, Inc.
  • Bristol-Myers Squibb Company
  • Cellectis SA
  • Daiichi Sankyo Company, Limited
  • Fate Therapeutics, Inc.
  • Gilead Sciences, Inc.
  • GlaxoSmithKline plc
  • Iovance Biotherapeutics, Inc.
  • Johnson & Johnson
  • Kite Pharma
  • Merck KGaA
  • Novartis AG
  • Pfizer Inc.
  • Regeneron Pharmaceuticals, Inc.
  • Roche Holding AG
  • Sanofi
  • Seagen Inc.
Product Code: MRR-4330CC794A6B

The Cancer Immunotherapy Market was valued at USD 81.74 billion in 2025 and is projected to grow to USD 86.14 billion in 2026, with a CAGR of 5.73%, reaching USD 120.75 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 81.74 billion
Estimated Year [2026] USD 86.14 billion
Forecast Year [2032] USD 120.75 billion
CAGR (%) 5.73%

Foundational overview of cancer immunotherapy evolution highlighting clinical progress, operational challenges, and strategic imperatives for stakeholders

Cancer immunotherapy has moved from a promising scientific concept to a central pillar of oncology care, driven by a sustained wave of clinical advances and regulatory milestones. Over the past decade, therapies that harness the immune system have redefined treatment paradigms for both hematologic malignancies and a growing set of solid tumors, creating meaningful durable responses for many patient subgroups. This evolution has been propelled by a convergence of technological improvements in cell engineering, precision biomarker assays, and an expanding repertoire of monoclonal antibodies, vaccines, and viral vectors.

As research continues to mature, stakeholders across industry, academia, and clinical practice face a new set of operational and strategic questions. Developers must balance the scientific complexity of combination regimens with the logistical demands of manufacturing personalized products, while payers and health systems increasingly seek evidence of long-term value and manageable treatment pathways. Consequently, organizations planning therapeutics or services in this space must integrate translational science with pragmatic considerations such as supply chain resilience, regulatory alignment, and patient access models to realize clinical benefit at scale.

This executive summary synthesizes current dynamics, regulatory and commercial headwinds, and actionable avenues for stakeholders to navigate the changing competitive and clinical environment. The goal is to offer a clear, evidence-aligned narrative that supports decision-making without obscuring the heterogeneity of tumor biology, therapeutic modalities, or care delivery contexts.

Critical transformative trends reshaping immuno-oncology including technological innovation, personalized strategies, and operational modernization across the value chain

The landscape of cancer immunotherapy is undergoing transformative shifts driven by a combination of scientific breakthroughs, regulatory adaptations, and evolving stakeholder expectations. First, the maturation of cell therapies, particularly chimeric antigen receptor T cells, has expanded beyond early successes in hematologic indications toward engineered constructs and allogeneic approaches designed to broaden applicability and reduce time-to-treatment. Parallel advances in checkpoint inhibition have been complemented by more nuanced approaches to immune modulation, including bispecific molecules and next-generation antibody formats that seek improved specificity and toxicity profiles.

Second, translational science is accelerating personalized approaches-neoantigen vaccines, tumor-infiltrating lymphocyte optimization, and multiplexed biomarker-driven trials-that demand more intricate trial designs and real-world evidence capture. As a result, collaborations that pair clinical expertise with diagnostic and bioinformatics capabilities are becoming essential. Third, manufacturing and supply chain innovations, including automation, closed-system processing, and regionalized production hubs, are shifting how developers plan scale-up and commercialization, reducing some barriers but introducing new capital and regulatory complexities.

Fourth, market and payer dynamics are influencing how therapies are evaluated, with a pronounced emphasis on long-term outcomes, value-based contracting, and healthcare system integration. Collectively, these shifts are redefining competitive advantage: scientific novelty alone is insufficient without credible development pathways, robust operational execution, and payer-aligned evidence generation. The combination of these elements will determine which programs progress from clinical promise to sustainable clinical and commercial impact.

Assessment of how evolving tariff policies in 2025 could alter supply chains, manufacturing strategies, and commercial positioning across immunotherapy stakeholders

The introduction of new tariff policies in the United States during 2025 has the potential to exert a cumulative impact across the cancer immunotherapy ecosystem by altering costs, supply chain configurations, and sourcing decisions. Key inputs for biologic and cell therapy manufacturing-specialized reagents, single-use consumables, bioprocessing equipment, and cold-chain logistics services-are often sourced globally. An increase in import duties or customs friction can elevate landed costs, prompt inventory rebalancing, and accelerate efforts to qualify alternative suppliers. Consequently, research and development timelines may experience pressure as procurement lead times extend and contingency planning becomes a material component of program risk management.

In response to tariff-driven cost pressures, many stakeholders may pursue nearshoring or domestic manufacturing partnerships to reduce exposure to cross-border trade volatility and maintain control over critical production steps. Such strategic reorientation could increase upfront capital deployment but may also yield long-term advantages in supply continuity and regulatory oversight. Moreover, higher input costs will heighten scrutiny of manufacturing efficiency, process intensification, and yield optimization, incentivizing investments in automation, closed systems, and digital monitoring to protect margins while preserving quality.

Finally, the cumulative effects of tariff changes will likely influence commercial strategies including pricing negotiations, payer contracting, and the staging of product launches. Organizations that proactively reassess supplier relationships, prioritize resilient manufacturing pathways, and transparently demonstrate cost and outcome value to payers will be better positioned to mitigate financial and operational disruption in a tariff-influenced market environment.

Comprehensive segmentation analysis revealing where therapeutic modalities, mechanisms, indications, and care settings create distinct development and commercialization pathways

A nuanced segmentation framework illuminates where clinical differentiation and commercial opportunity intersect across therapy types, mechanisms, lines of therapy, administration routes, indications, and end users. Based on Therapy Type, programs span Cancer Vaccines, CAR-T Therapy, CTLA-4 Inhibitors, Oncolytic Virus Therapy, PD-1 Inhibitors, and PD-L1 Inhibitors, each presenting distinct development challenges and clinical positioning considerations; vaccine strategies emphasize antigen selection and delivery platforms, whereas cell therapies demand manufacturing innovation and patient-centric logistics. Based on Mechanism Of Action, the field encompasses Adoptive Cell Transfer, Checkpoint Inhibitors, Cytokine Therapy, Oncolytic Virus Therapy, and Vaccine Therapy, and this mechanistic diversity requires tailored biomarker strategies, safety monitoring frameworks, and combination hypotheses to maximize efficacy while managing toxicity.

Based on Line Of Therapy, therapeutic opportunities and payer expectations vary significantly between First Line, Second Line, Third Line, and Fourth Line And Beyond, with earlier-line approvals necessitating higher-evidence thresholds and clearer comparative benefit; consequently, developers should plan sequencing strategies that align trial design with expected reimbursement scenarios. Based on Route Of Administration, distinctions among Intratumoral, Intravenous, and Subcutaneous approaches influence clinical workflow, patient burden, and site-of-care economics, shaping adoption pathways across hospitals and clinics. Based on Indication, the landscape bifurcates into Hematologic Malignancies and Solid Tumors, with the former further segmented into Leukemia, Lymphoma, and Multiple Myeloma and the latter into Breast Cancer, Colorectal Cancer, Lung Cancer, and Melanoma, each indication presenting unique tumor microenvironmental considerations and biomarker profiles that inform patient selection and combination strategies.

Based on End User, hospitals, research institutes, and specialty clinics play differentiated roles in clinical trial accrual, product administration, and post-market evidence generation; hospitals often lead high-complexity administrations and inpatient monitoring, research institutes drive translational science and early-phase innovation, while specialty clinics enable outpatient delivery models that can improve throughput and patient convenience. Together, this segmentation highlights where scientific focus, operational investment, and commercial engagement should be concentrated to address unmet needs and optimize development trajectories.

Region-specific dynamics and strategic considerations for regulatory engagement, evidence generation, and manufacturing across global immunotherapy markets

Regional dynamics shape clinical trial design, regulatory engagement, manufacturing investment, and access strategies, demanding region-specific approaches that accommodate regulatory frameworks, reimbursement systems, and healthcare infrastructure. In the Americas, regulatory agencies and payers emphasize robust outcomes evidence and real-world data, while large research networks and venture and corporate investment have accelerated first-in-human studies and commercialization pathways; consequently, organizations often prioritize North American clinical validation and payer dialogue early in development to underpin broader market access plans. The Americas also host concentrated manufacturing and logistics capabilities, which supports rapid scale-up but requires careful coordination with hospital and specialty clinic administration models.

In Europe, Middle East & Africa, regulatory diversity and heterogeneous reimbursement environments necessitate multi-jurisdictional regulatory strategies and differentiated pricing approaches. European health technology assessment bodies place particular weight on comparative effectiveness and cost-effectiveness assessments, influencing trial endpoints and evidence generation plans. Additionally, emerging markets across the Middle East & Africa present opportunities for capacity building and pilot access programs but require tailored operational partnerships and investment in cold-chain and training infrastructure.

In Asia-Pacific, accelerated trial recruitment, growing biotech innovation hubs, and increasing local manufacturing capacity are shaping regional strategies; countries in the region vary in regulatory timelines and local clinical expectations, prompting companies to calibrate development plans to leverage speed to data while ensuring quality and regulatory alignment. Cross-region collaboration, such as bridging studies and harmonized regulatory submissions, can reduce time-to-patient access and support global labeling strategies, provided sponsors anticipate regional clinical practice patterns and payer requirements.

Competitive dynamics and partnership-based strategies revealing how execution, manufacturing scale, and platform differentiation drive long-term value creation

The competitive landscape is characterized by incumbent immuno-oncology leaders and a large cohort of emerging biotechs pursuing platform innovation, niche indications, or combination regimens. Established developers have leveraged deep clinical datasets and manufacturing footprints to secure broad label expansions and to negotiate value-based arrangements with payers, whereas smaller firms often focus on differentiated biology, novel antigen targets, or enabling technologies that improve manufacturability and patient access.

Across the ecosystem, strategic partnerships between developers, contract development and manufacturing organizations, diagnostic providers, and academic centers have become increasingly common as a means to accelerate clinical translation and de-risk capital-intensive steps. These alliances frequently address discrete gaps such as vector manufacturing, T-cell engineering, or companion diagnostic validation, enabling faster trial starts and improved operational scalability. In parallel, service providers offering automation, analytics, and patient management tools are emerging as critical enablers for both personalized and standardized therapeutic approaches.

Intellectual property positioning, clinical differentiation, and demonstrated ability to execute complex supply chains remain decisive factors in value creation. Firms that combine robust clinical programs with scalable manufacturing, payer-aligned evidence strategies, and strong collaborative networks will retain strategic advantage. At the same time, new entrants that deliver platform-level improvements in safety, cost, or ease-of-use can rapidly gain relevance through licensing or co-development agreements.

Actionable strategic recommendations for aligning clinical development, manufacturing resilience, and payer engagement to accelerate adoption and value realization

Leaders planning to navigate the next phase of immuno-oncology advancement should adopt integrated strategies that align science, operations, and commercialization. First, prioritize modular development plans that allow for adaptive trial designs and biomarker-enriched cohorts to demonstrate meaningful benefit while preserving flexibility for label expansion and combinations. Early engagement with regulatory bodies and payers is essential to define clinically relevant endpoints and acceptable evidence packages that support durable reimbursement outcomes. Second, invest in manufacturing resilience by exploring regional production hubs, automation, and supplier diversification to mitigate geopolitical and tariff-related disruption while maintaining quality and compliance standards.

Third, cultivate strategic partnerships spanning diagnostics, contract manufacturing, and clinical network collaborators to accelerate translational pathways and reduce time-to-patient. By leveraging external expertise, organizations can focus internal resources on core differentiators such as target biology and clinical execution. Fourth, design patient-centric delivery models that reduce burden, enable outpatient administration where feasible, and integrate digital tools for monitoring and outcomes capture. These models enhance adherence and produce real-world evidence that reinforces payer negotiations and clinical adoption.

Finally, maintain disciplined portfolio management that balances novel, high-risk science with programs offering clearer paths to clinical and commercial viability. Establishing cross-functional governance for prioritization, risk monitoring, and go-to-market readiness will enable faster, more confident decisions as the scientific and policy environment evolves.

Robust multi-source research methodology integrating expert interviews, regulatory analysis, and operational assessments to generate actionable industry insights

The research synthesis draws on a multi-source methodology designed to integrate scientific literature, regulatory guidance, expert interviews, and operational insights to build a coherent narrative aligned with industry practice. Primary qualitative inputs included structured interviews with clinical investigators, manufacturing leads, payers, and commercial strategists to surface pragmatic barriers and enablers across development and delivery pathways. These interviews were complemented by a systematic review of peer-reviewed publications, regulatory approvals, and public filings to ensure the analysis reflects recent scientific advances and policy shifts.

Additionally, the methodology incorporated operational assessments of manufacturing and supply chain considerations through engagements with contract development and manufacturing organizations and logistics specialists. This allowed for an informed appraisal of practical constraints such as lead times, cold-chain requirements, and capacity scaling. Analytical synthesis emphasized cross-validation, pairing qualitative perspectives with documented clinical and regulatory milestones to reduce bias and enhance actionability. Throughout the research process, attention was paid to transparency of assumptions, the provenance of insights, and the identification of areas where further primary data collection could refine conclusions.

This multi-dimensional approach enables stakeholders to interpret findings in the context of their own strategic priorities while recognizing the heterogeneity inherent in therapeutic modalities, geographic markets, and care delivery models.

Concluding synthesis emphasizing the necessity of integrated scientific, operational, and commercial strategies to realize the full promise of immuno-oncology

Cancer immunotherapy stands at an inflection point where scientific progress must be matched by operational excellence and strategic clarity to sustain momentum. Novel modalities and combination strategies continue to expand the therapeutic toolkit, but their ultimate impact will depend on the ability of stakeholders to navigate complex manufacturing requirements, diverse regulatory expectations, and evolving payer evidence demands. Organizations that proactively adapt development strategies to incorporate biomarker-driven patient selection, resilient supply chains, and payer-aligned evidence will be better positioned to translate clinical promise into durable patient benefit.

Moreover, the growing interplay between regional regulatory environments and global commercialization strategies underscores the necessity of harmonized evidence plans and flexible manufacturing footprints. As new policy and trade dynamics emerge, including tariff considerations, the capacity to rapidly adjust sourcing and production approaches becomes a competitive advantage. In conclusion, the path forward requires integrated leadership across science, operations, and commercial functions to ensure that innovations in immuno-oncology are delivered efficiently, equitably, and with demonstrable value for patients and health systems alike.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Cancer Immunotherapy Market, by Therapy Type

  • 8.1. Cancer Vaccines
  • 8.2. CAR-T Therapy
  • 8.3. CTLA-4 Inhibitors
  • 8.4. Oncolytic Virus Therapy
  • 8.5. PD-1 Inhibitors
  • 8.6. PD-L1 Inhibitors

9. Cancer Immunotherapy Market, by Mechanism Of Action

  • 9.1. Adoptive Cell Transfer
  • 9.2. Checkpoint Inhibitors
  • 9.3. Cytokine Therapy
  • 9.4. Oncolytic Virus Therapy
  • 9.5. Vaccine Therapy

10. Cancer Immunotherapy Market, by Line Of Therapy

  • 10.1. First Line
  • 10.2. Fourth Line And Beyond
  • 10.3. Second Line
  • 10.4. Third Line

11. Cancer Immunotherapy Market, by Route Of Administration

  • 11.1. Intratumoral
  • 11.2. Intravenous
  • 11.3. Subcutaneous

12. Cancer Immunotherapy Market, by Indication

  • 12.1. Hematologic Malignancies
    • 12.1.1. Leukemia
    • 12.1.2. Lymphoma
    • 12.1.3. Multiple Myeloma
  • 12.2. Solid Tumors
    • 12.2.1. Breast Cancer
    • 12.2.2. Colorectal Cancer
    • 12.2.3. Lung Cancer
    • 12.2.4. Melanoma

13. Cancer Immunotherapy Market, by End User

  • 13.1. Hospitals
  • 13.2. Research Institutes
  • 13.3. Specialty Clinics

14. Cancer Immunotherapy Market, by Region

  • 14.1. Americas
    • 14.1.1. North America
    • 14.1.2. Latin America
  • 14.2. Europe, Middle East & Africa
    • 14.2.1. Europe
    • 14.2.2. Middle East
    • 14.2.3. Africa
  • 14.3. Asia-Pacific

15. Cancer Immunotherapy Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. Cancer Immunotherapy Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. United States Cancer Immunotherapy Market

18. China Cancer Immunotherapy Market

19. Competitive Landscape

  • 19.1. Market Concentration Analysis, 2025
    • 19.1.1. Concentration Ratio (CR)
    • 19.1.2. Herfindahl Hirschman Index (HHI)
  • 19.2. Recent Developments & Impact Analysis, 2025
  • 19.3. Product Portfolio Analysis, 2025
  • 19.4. Benchmarking Analysis, 2025
  • 19.5. Amgen Inc.
  • 19.6. AstraZeneca PLC
  • 19.7. BeiGene, Ltd.
  • 19.8. bluebird bio, Inc.
  • 19.9. Bristol-Myers Squibb Company
  • 19.10. Cellectis S.A.
  • 19.11. Daiichi Sankyo Company, Limited
  • 19.12. Fate Therapeutics, Inc.
  • 19.13. Gilead Sciences, Inc.
  • 19.14. GlaxoSmithKline plc
  • 19.15. Iovance Biotherapeutics, Inc.
  • 19.16. Johnson & Johnson
  • 19.17. Kite Pharma
  • 19.18. Merck KGaA
  • 19.19. Novartis AG
  • 19.20. Pfizer Inc.
  • 19.21. Regeneron Pharmaceuticals, Inc.
  • 19.22. Roche Holding AG
  • 19.23. Sanofi
  • 19.24. Seagen Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL CANCER IMMUNOTHERAPY MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL CANCER IMMUNOTHERAPY MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY THERAPY TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY LINE OF THERAPY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 13. UNITED STATES CANCER IMMUNOTHERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 14. CHINA CANCER IMMUNOTHERAPY MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY CANCER VACCINES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY CANCER VACCINES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY CANCER VACCINES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY CAR-T THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY CAR-T THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY CAR-T THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY CTLA-4 INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY CTLA-4 INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY CTLA-4 INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY ONCOLYTIC VIRUS THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY ONCOLYTIC VIRUS THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY ONCOLYTIC VIRUS THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY PD-1 INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY PD-1 INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY PD-1 INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY PD-L1 INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY PD-L1 INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY PD-L1 INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY ADOPTIVE CELL TRANSFER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY ADOPTIVE CELL TRANSFER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY ADOPTIVE CELL TRANSFER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY CHECKPOINT INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY CHECKPOINT INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY CHECKPOINT INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY CYTOKINE THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY CYTOKINE THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY CYTOKINE THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY ONCOLYTIC VIRUS THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY ONCOLYTIC VIRUS THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY ONCOLYTIC VIRUS THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY VACCINE THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY VACCINE THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY VACCINE THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY FIRST LINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY FIRST LINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY FIRST LINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY FOURTH LINE AND BEYOND, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY FOURTH LINE AND BEYOND, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY FOURTH LINE AND BEYOND, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY SECOND LINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY SECOND LINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY SECOND LINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY THIRD LINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY THIRD LINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY THIRD LINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY INTRATUMORAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY INTRATUMORAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY INTRATUMORAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY LEUKEMIA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY LEUKEMIA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY LEUKEMIA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY LYMPHOMA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY LYMPHOMA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY LYMPHOMA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY MULTIPLE MYELOMA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY MULTIPLE MYELOMA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY MULTIPLE MYELOMA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY SOLID TUMORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY SOLID TUMORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY SOLID TUMORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY BREAST CANCER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY BREAST CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY COLORECTAL CANCER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY COLORECTAL CANCER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY COLORECTAL CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY LUNG CANCER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY LUNG CANCER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY LUNG CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY MELANOMA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY MELANOMA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY MELANOMA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 101. AMERICAS CANCER IMMUNOTHERAPY MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 102. AMERICAS CANCER IMMUNOTHERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 103. AMERICAS CANCER IMMUNOTHERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 104. AMERICAS CANCER IMMUNOTHERAPY MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 105. AMERICAS CANCER IMMUNOTHERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 106. AMERICAS CANCER IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 107. AMERICAS CANCER IMMUNOTHERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2032 (USD MILLION)
  • TABLE 108. AMERICAS CANCER IMMUNOTHERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 109. AMERICAS CANCER IMMUNOTHERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 110. NORTH AMERICA CANCER IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 111. NORTH AMERICA CANCER IMMUNOTHERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 112. NORTH AMERICA CANCER IMMUNOTHERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 113. NORTH AMERICA CANCER IMMUNOTHERAPY MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 114. NORTH AMERICA CANCER IMMUNOTHERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 115. NORTH AMERICA CANCER IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 116. NORTH AMERICA CANCER IMMUNOTHERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2032 (USD MILLION)
  • TABLE 117. NORTH AMERICA CANCER IMMUNOTHERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 118. NORTH AMERICA CANCER IMMUNOTHERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 119. LATIN AMERICA CANCER IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 120. LATIN AMERICA CANCER IMMUNOTHERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 121. LATIN AMERICA CANCER IMMUNOTHERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 122. LATIN AMERICA CANCER IMMUNOTHERAPY MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 123. LATIN AMERICA CANCER IMMUNOTHERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 124. LATIN AMERICA CANCER IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 125. LATIN AMERICA CANCER IMMUNOTHERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2032 (USD MILLION)
  • TABLE 126. LATIN AMERICA CANCER IMMUNOTHERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 127. LATIN AMERICA CANCER IMMUNOTHERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 128. EUROPE, MIDDLE EAST & AFRICA CANCER IMMUNOTHERAPY MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 129. EUROPE, MIDDLE EAST & AFRICA CANCER IMMUNOTHERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 130. EUROPE, MIDDLE EAST & AFRICA CANCER IMMUNOTHERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 131. EUROPE, MIDDLE EAST & AFRICA CANCER IMMUNOTHERAPY MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 132. EUROPE, MIDDLE EAST & AFRICA CANCER IMMUNOTHERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 133. EUROPE, MIDDLE EAST & AFRICA CANCER IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 134. EUROPE, MIDDLE EAST & AFRICA CANCER IMMUNOTHERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2032 (USD MILLION)
  • TABLE 135. EUROPE, MIDDLE EAST & AFRICA CANCER IMMUNOTHERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 136. EUROPE, MIDDLE EAST & AFRICA CANCER IMMUNOTHERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 137. EUROPE CANCER IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 138. EUROPE CANCER IMMUNOTHERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 139. EUROPE CANCER IMMUNOTHERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 140. EUROPE CANCER IMMUNOTHERAPY MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 141. EUROPE CANCER IMMUNOTHERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 142. EUROPE CANCER IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 143. EUROPE CANCER IMMUNOTHERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2032 (USD MILLION)
  • TABLE 144. EUROPE CANCER IMMUNOTHERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 145. EUROPE CANCER IMMUNOTHERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 146. MIDDLE EAST CANCER IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 147. MIDDLE EAST CANCER IMMUNOTHERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 148. MIDDLE EAST CANCER IMMUNOTHERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 149. MIDDLE EAST CANCER IMMUNOTHERAPY MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 150. MIDDLE EAST CANCER IMMUNOTHERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 151. MIDDLE EAST CANCER IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 152. MIDDLE EAST CANCER IMMUNOTHERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2032 (USD MILLION)
  • TABLE 153. MIDDLE EAST CANCER IMMUNOTHERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 154. MIDDLE EAST CANCER IMMUNOTHERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 155. AFRICA CANCER IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 156. AFRICA CANCER IMMUNOTHERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 157. AFRICA CANCER IMMUNOTHERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 158. AFRICA CANCER IMMUNOTHERAPY MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 159. AFRICA CANCER IMMUNOTHERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 160. AFRICA CANCER IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 161. AFRICA CANCER IMMUNOTHERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2032 (USD MILLION)
  • TABLE 162. AFRICA CANCER IMMUNOTHERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 163. AFRICA CANCER IMMUNOTHERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 164. ASIA-PACIFIC CANCER IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 165. ASIA-PACIFIC CANCER IMMUNOTHERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 166. ASIA-PACIFIC CANCER IMMUNOTHERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 167. ASIA-PACIFIC CANCER IMMUNOTHERAPY MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 168. ASIA-PACIFIC CANCER IMMUNOTHERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 169. ASIA-PACIFIC CANCER IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 170. ASIA-PACIFIC CANCER IMMUNOTHERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2032 (USD MILLION)
  • TABLE 171. ASIA-PACIFIC CANCER IMMUNOTHERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 172. ASIA-PACIFIC CANCER IMMUNOTHERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 173. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 174. ASEAN CANCER IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 175. ASEAN CANCER IMMUNOTHERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 176. ASEAN CANCER IMMUNOTHERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 177. ASEAN CANCER IMMUNOTHERAPY MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 178. ASEAN CANCER IMMUNOTHERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 179. ASEAN CANCER IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 180. ASEAN CANCER IMMUNOTHERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2032 (USD MILLION)
  • TABLE 181. ASEAN CANCER IMMUNOTHERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 182. ASEAN CANCER IMMUNOTHERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 183. GCC CANCER IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 184. GCC CANCER IMMUNOTHERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 185. GCC CANCER IMMUNOTHERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 186. GCC CANCER IMMUNOTHERAPY MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 187. GCC CANCER IMMUNOTHERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 188. GCC CANCER IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 189. GCC CANCER IMMUNOTHERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2032 (USD MILLION)
  • TABLE 190. GCC CANCER IMMUNOTHERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 191. GCC CANCER IMMUNOTHERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 192. EUROPEAN UNION CANCER IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 193. EUROPEAN UNION CANCER IMMUNOTHERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 194. EUROPEAN UNION CANCER IMMUNOTHERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 195. EUROPEAN UNION CANCER IMMUNOTHERAPY MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 196. EUROPEAN UNION CANCER IMMUNOTHERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 197. EUROPEAN UNION CANCER IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 198. EUROPEAN UNION CANCER IMMUNOTHERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2032 (USD MILLION)
  • TABLE 199. EUROPEAN UNION CANCER IMMUNOTHERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 200. EUROPEAN UNION CANCER IMMUNOTHERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 201. BRICS CANCER IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 202. BRICS CANCER IMMUNOTHERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 203. BRICS CANCER IMMUNOTHERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 204. BRICS CANCER IMMUNOTHERAPY MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 205. BRICS CANCER IMMUNOTHERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 206. BRICS CANCER IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 207. BRICS CANCER IMMUNOTHERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2032 (USD MILLION)
  • TABLE 208. BRICS CANCER IMMUNOTHERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 209. BRICS CANCER IMMUNOTHERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 210. G7 CANCER IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 211. G7 CANCER IMMUNOTHERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 212. G7 CANCER IMMUNOTHERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 213. G7 CANCER IMMUNOTHERAPY MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 214. G7 CANCER IMMUNOTHERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 215. G7 CANCER IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 216. G7 CANCER IMMUNOTHERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2032 (USD MILLION)
  • TABLE 217. G7 CANCER IMMUNOTHERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 218. G7 CANCER IMMUNOTHERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 219. NATO CANCER IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 220. NATO CANCER IMMUNOTHERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 221. NATO CANCER IMMUNOTHERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 222. NATO CANCER IMMUNOTHERAPY MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 223. NATO CANCER IMMUNOTHERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 224. NATO CANCER IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 225. NATO CANCER IMMUNOTHERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2032 (USD MILLION)
  • TABLE 226. NATO CANCER IMMUNOTHERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 227. NATO CANCER IMMUNOTHERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 228. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 229. UNITED STATES CANCER IMMUNOTHERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 230. UNITED STATES CANCER IMMUNOTHERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 231. UNITED STATES CANCER IMMUNOTHERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 232. UNITED STATES CANCER IMMUNOTHERAPY MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 233. UNITED STATES CANCER IMMUNOTHERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 234. UNITED STATES CANCER IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 235. UNITED STATES CANCER IMMUNOTHERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2032 (USD MILLION)
  • TABLE 236. UNITED STATES CANCER IMMUNOTHERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 237. UNITED STATES CANCER IMMUNOTHERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 238. CHINA CANCER IMMUNOTHERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 239. CHINA CANCER IMMUNOTHERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 240. CHINA CANCER IMMUNOTHERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 241. CHINA CANCER IMMUNOTHERAPY MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 242. CHINA CANCER IMMUNOTHERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 243. CHINA CANCER IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 244. CHINA CANCER IMMUNOTHERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, 2018-2032 (USD MILLION)
  • TABLE 245. CHINA CANCER IMMUNOTHERAPY MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 246. CHINA CANCER IMMUNOTHERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)